Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
about
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVIntegrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo AcidsResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceNovel therapeutic strategies targeting HIV integraseNew Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of ActionDolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trialsNon-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cellsA novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzeeCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Dolutegravir: clinical efficacy and role in HIV therapy.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.New first and second generation inhibitors of human immunodeficiency virus-1 integrase.A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasmaAntiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfileEffect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjectsDolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integraseEffect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesPharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects.Discovery of a Potent HIV Integrase Inhibitor that Leads to a Prodrug with Significant anti-HIV Activity.Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.Potential benefit of dolutegravir once daily: efficacy and safety.Solid-state tautomeric structure and invariom refinement of a novel and potent HIV integrase inhibitor.A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humansThe Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults
P2860
Q26778450-A76F25C5-2064-41DD-A967-07F48C1848DAQ26799712-96C0B0BA-2234-4BD9-AB36-50F84D5ED9D4Q26800036-BC1EF607-382A-472A-82FC-511DEC8AB558Q26801286-85B5F67F-E6BB-441B-BA7C-694260E5EC1AQ27003960-6B17499A-0868-4C5D-9E65-4515DB7425ABQ27678745-CDF9C84B-9CDE-41DC-8137-D71288589399Q28077053-06919AF1-65BD-4172-9D24-FE73EA0CBDA3Q28536951-70832639-72CD-4436-8BDB-A8E90AB4F9AAQ30429621-D400D8E4-3282-4742-91E4-8C9DD0608561Q33442370-3F9D320C-942C-4D40-9729-9405C4DFF8EBQ33680234-D79A4CF8-DC78-4D57-83BC-05C112904F52Q33686465-75EB329A-2256-4855-872C-691F59952539Q33725024-2DC660AB-9FBC-4362-9F87-75CB64B91607Q33888718-91AC472B-107A-4BB1-80FD-25F5E2A2AB85Q33911400-941A097C-90BF-4431-9B00-7919D5FB49D9Q34059575-0F3B4E7D-9ACF-4383-8C49-25E72B8A330BQ34151623-D510C7A8-DD9F-4347-A450-ACB4181F6482Q34168983-AB944FD7-74AA-4D84-B073-95D747577E99Q34186375-BBB9E33B-D3AC-4CE4-9F24-9378E2AD6623Q34496927-03A71B8E-9D33-4A20-8E2E-95F1DFFEEE48Q34540677-7578B9CB-5E23-4955-8C19-86045C52899BQ34596882-29E9FE47-EEF7-4853-A2FA-70770BE89108Q34726183-E065F823-5EA0-400C-BB37-4968CA3DD161Q34770674-39333F62-1651-4F56-9F26-9B473FB532D0Q35120618-31D66779-CB54-4C00-8B38-F86BDC3CBB7DQ35432739-5CF4D603-9831-4091-BBEE-F300C3A4E7E4Q35532581-86DA2746-2B2A-4C78-AFB7-234B198A3DBBQ35743198-9CE6C5A0-A4EF-448D-B195-B3A37FC7A536Q35756542-C62F1D09-F52A-448E-911A-ECD39F6726B8Q35760170-51B835EF-A33A-4732-A04A-B702F84AA64DQ35806381-2FAB6F15-7187-4230-847E-2232D5A09CA2Q35944477-69367B41-848C-45E3-8389-4A0B6C4BC9B9Q36146699-C3965C81-8D67-47AF-8FF0-D53F8BFCF27AQ36603416-4C2BA635-0727-4CFB-8AA6-6769EB437CCCQ36659109-3812A00C-97B3-4EAF-A75B-B0F83810F831Q36729925-86FFC5CB-26F4-404E-9BEC-25CAADAA1E1BQ37036624-4A570999-94B6-487F-833B-9DAB1E3FE683Q37071977-DBC78C4A-839B-486F-8A27-7C56119ACD66Q37095708-2399DCB6-1276-42AE-9097-885064804BEDQ37244858-AE3A6046-A466-4446-B0EB-41965B6B2482
P2860
Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@ast
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@en
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@nl
type
label
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@ast
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@en
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@nl
prefLabel
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@ast
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@en
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and safety of ...... ibitor, in healthy volunteers.
@en
P2093
Julie Borland
Sherene Min
Shuguang Chen
Stephen C Piscitelli
Tamio Fujiwara
P2860
P304
P356
10.1128/AAC.00842-09
P407
P577
2009-11-02T00:00:00Z